Corticosteroid withdrawal may reduce insulin resistance; however, it could also influence pancreatic autoantibody profile in simultaneous pancreas–kidney (SPK) transplant patients.
Objective:
To evaluate the effect of corticosteroid withdrawal on glucose metabolism and anti-glutamic acid decarboxylase (GAD) antibody titers in SPK patients with type 1 diabetes after 12 months of follow-up.
Design:
In this retrospective study, fasting glucose and glycated hemoglobin (A1c) were compared before and after 3, 6, and 12 months of corticosteroid withdrawal in 80 SPK patients. In addition, weight, anti-GAD, and C-peptide levels were compared before and after withdrawal. Finally, fasting and postglucose, insulin, and C-peptide levels were compared before and after withdrawal in 25 patients undergoing oral glucose tolerance test (OGTT).
Results:
Fasting glucose levels did not change during corticosteroid discontinuation. After 12 months, A1c slightly increased from 4.6% (0.4%) to 4.8% (0.6%) (P < .01) and C-peptide decreased from 2.8 (1.1) ng/mL to 2.4 (1.3) ng/mL (P <. 01). In patients submitted to OGTT, glucose, insulin, and C-peptide levels did not change. There was no alteration in the proportion of anti-GAD positive tests (41% vs 45%). Anti-GAD titers remained stable or decreased in 70% of positive patients.
Conclusion:
Corticosteroid withdrawal has no significant effect on glucose metabolism and on anti-GAD profile among SPK patients.
CitterioF. Steroid side effects and their impact on transplantation outcome. Transplantation. 2001;72(12 suppl):s75–s80.
2.
RedfieldRRScaleaJROdoricoJS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant. 2015;20(1):94–102. doi:10.1097/MOT.0000000000000146.
3.
SharifAHeckingMde VriesAP. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992–2000. doi:10.1111/ajt.12850.
4.
KnightSRMorrisPJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010;89(1):1–14. doi:10.1097/TP.0b013e3181c518cc.
5.
ChakkeraHAMandarinoLJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):647–652. doi:10.1097/TP.0b013e31826e592e.
6.
SutherlandDEGoetzFCSibleyRK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38(suppl 1):85–87.
7.
PuglieseAReijonenHKNepomJBurkeGWIII. Recurrence of autoimmunity in pancreas transplant patients: research update. Diabetes Manag (Lond). 2011;1(2):229–238.
8.
PetruzzoPAndreelliFMcGregorB. Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. Diabetes Metab. 2000;26(3):215–218.
9.
KaufmanDBLeventhalJRKoffronAJ. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation. 2002;73(2):169–177.
10.
FreiseCEKangSMFengSHiroseRStockP. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg. 2003;138(10):1121–1125.
11.
GruessnerRWKandaswamyRHumarAGruessnerACSutherlandDE. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation. 2005;79(9):1184–1189.
12.
RajabAPelletierRPFergusonRMElkhammasEABumgardnerGLHenryML. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients. Transplantation. 2007;84(9):1131–1137.
13.
MonteroNWebsterACRoyuelaAZamoraJCrespo BarrioMPascualJ. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev. 2014;9:cd007669. doi:10.1002/14651858.CD007669.pub2.
14.
KandaswamyRSkeansMAGustafsonSK. OPTN/SRTR 2013 Annual Data Report: pancreas. Am J Transplant. 2015;15(suppl 2):1–20. doi:10.1111/ajt.13196.
15.
JordanMLChakrabartiPLukeP. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000;69(2):265–271.
16.
SecchiAMalaiseJCaldaraR; Euro-SPK Study Group. Metabolic results 3 years after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 2005;20(suppl 2):ii18–ii24, ii62.
17.
KandaswamyRKhwajaKGruessnerACGruessnerRWPulkrabeckLSutherlandDER. A prospective randomized trial of steroid-free maintenance regimens vs delayed steroid withdrawal using sirolimus/tacrolimus regimen in simultaneous pancreas-kidney transplants [abstract]. Am J Transplant. 2003;3(suppl 5):530.
DuijnhovenEMBootsJMChristiaansMHWolffenbuttelBHvan HooffJP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12(3):583–588.
20.
Van DuijnhovenEMChristiaansMHBootsJMNiemanFHWolffenbuttelBHvan HooffJP. Glucose metabolism in the first 3 years after renal transplantation in patients on tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol. 2002;13(1):213–220.
MidtvedtKHjelmesaethJHartmannA. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15(12):3233–3239.
23.
DieterleCDHierlFXGuttB. Insulin and islet autoantibodies after pancreas transplantation. Transpl Int. 2005;18(12):1361–1365.
24.
MartinsLSHenriquesACFonsecaIM. Pancreatic autoantibodies after pancreas-kidney transplantation—do they matter?Clin Transplant. 2014;28(4):462–469. doi:10.1111/ctr.12337.
25.
EsmatjesERodríguez-VillarCRicartMJ. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation. 1998;66(1):128–131.
26.
Da SilvaMThivoletCLefrançoisN. Combined analysis of autoantibodies against beta-cells for prediction of pancreas allograft failure. Transplant Proc. 2000;32(8):2773.
27.
SantamariaPNakhlehRESutherlandDEBarbosaJJ. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes. 1992;41(1):53–61.
28.
TydenGReinholtFPSundkvistGBolinderJ. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med. 1996;335(12):860–863.
29.
MartinsLMalheiroJHenriquesAC. Pancreas-kidney transplantation and the evolution of pancreatic autoantibodies. Transplant Proc. 2009;41(3):913–915. doi:10.1016/j.transproceed.2009.01.068.
